News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Melanoma New Zealand delighted with OPDIVO registration

2 May 2016

Melanoma New Zealand delighted with OPDIVO registration

Melanoma New Zealand is delighted that anti-PD1 immunotherapy OPDIVO (Nivolumab) has been approved by Medsafe and is now a registered medicine in New Zealand.

Chief Executive Officer of Melanoma New Zealand, Linda Flay, says: “This is an important step for New Zealanders given that we have the highest incidence rate of melanoma in the world, and more than 300 New Zealanders lose their lives every year from melanoma.

“More than 4,500 new cases of melanoma are diagnosed in New Zealand each year. Of those classified as stage four, they currently have a life expectancy of around six to nine months.

"This is the second drug in this class to be registered in the last 12 months, and at last we are beginning to see new treatments coming through with immunotherapy drugs finally bringing hope to patients.”

Melanoma New Zealand Board Member, Dr Rosalie Fisher, says: “Immune checkpoint inhibition is currently the most effective treatment for malignant melanoma.

“OPDIVO shrinks or stabilises melanoma tumours in the majority of patients with advanced melanoma, and unequivocally lengthens the survival of these patients. More than one-third of patients treated with OPDIVO are still alive more than five years after starting treatment.

“These results are exceptional. It is disappointing that the only funded treatment in New Zealand is chemotherapy, which is usually ineffectual and now considered obsolete by international standards.

“OPDIVO works by blocking a specific protein, PD-1, unmasking the tumour and allowing the body’s own immune system to fight the cancer. It is safe and well-tolerated and promises long-term control of this difficult disease”

Mrs Flay adds: “While registration is a great step, it is vital patients now get funded access to an immunotherapy treatment.”

OPDIVO is currently under review by PHARMAC. It is the second anti-PD1 medicine to be registered in New Zealand and is already registered and/or in routine use in Australia, European Union, Japan and the United States


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Howard Davis Review: Reclaiming The N-Word - Spike Lee's BlacKkKlansman

Black resistance to institutional racism in the US has a long, tangled, and traumatic intellectual history. Although we may have assumed much too easily that white supremacists like David Duke had become marginalised as a political force, in reality they never really disappeared ... More>>

Howard Davis Review: The Minstrel in The Gallery - Sam Hunt's Selected Poems

Perhaps the most striking aspect of Sam Hunt's poetry is its quality of urgent authenticity. Encountering this latest compilation, the reader is immediately struck by its easy accessibility, tonal sincerity, and lack of linguistic pretension ... More>>

A Matter Of Fact: Truth In A Post-Truth World

How do we convincingly explain the difference between good information and misinformation? And conversely, how do we challenge our own pre-conceived notions of what we believe to be true? More>>


Scoop Review Of Books: The Road To Unfreedom

Valerie Morse: Yale professor of history Tim Snyder publishes a stunning account of the mechanisms of contemporary Russian power in US and European politics. In telling this story he presents both startling alarms for our own society and some mechanisms of resistance. More>>


Doing Our Bit: An Insider's Account Of New Zealand Political Campaigning

In 2013, Murdoch Stephens began a campaign to double New Zealand’s refugee quota. Over the next five years he built the campaign into a mainstream national movement – one that contributed to the first growth in New Zealand’s refugee quota in thirty years. More>>



  • Wellington
  • Christchurch
  • Auckland